Nitrous oxide, better known as laughing gas, is quietly emerging as one of the most intriguing rapid-acting options for people whose depression has not budged with standard pills or talk therapy. Instead of waiting weeks to see if a new antidepressant helps, some patients in clinical trials are feeling a lift in mood within hours of a single, carefully controlled inhalation session. The idea that a few measured breaths of an old anesthetic could interrupt years of entrenched despair is reshaping how I think about what “fast relief” from depression might realistically mean.
Researchers are not talking about party balloons or do-it-yourself cartridges, but about medical-grade nitrous oxide delivered in hospital or clinic settings, with close monitoring and strict dosing. Early studies suggest that this gas, long used to dull pain in dental chairs and operating rooms, can trigger meaningful improvements in people with major depressive disorder and treatment-resistant depression, sometimes after just one session and sometimes with benefits that linger for days or even weeks.
Why laughing gas is suddenly on psychiatry’s radar
The renewed attention to nitrous oxide in mental health starts with a stark problem: as many as one-third of people who take antidepressants do not improve enough to function or feel well. That treatment-resistant group has pushed clinicians to look beyond serotonin-focused drugs toward anesthetics that act on different brain systems, including ketamine and nitrous oxide. In that context, a series of trials led by Researchers at Washington University School of Medicine in St. Louis and the University of Chicago showed that carefully dosed nitrous oxide could relieve symptoms in people whose depression had resisted multiple medications, putting the gas squarely on psychiatry’s research agenda.
Those findings did not appear in isolation. Earlier work had already suggested that Nitrous oxide (laughing gas) has shown early promise as a rapidly acting antidepressant in patients with treatment-resistant depression, with small but carefully controlled trials hinting at robust mood changes. At the same time, clinicians at Barnes-Jewish Hospital were reporting that LAUGHING GAS RELIEVES TREATMENT RESISTANT DEPRESSION in people who had cycled through standard drugs without lasting benefit, reinforcing the sense that this familiar anesthetic might have a second life as a psychiatric tool.
How nitrous oxide works in the brain
What makes nitrous oxide so interesting is not just that it works quickly, but that it appears to work through a different molecular doorway than traditional antidepressants. Instead of primarily tweaking serotonin or norepinephrine, nitrous oxide interacts with glutamate signaling and inhibits the glutamatergic NMDA receptor, a mechanism that preclinical work has already linked to rapid mood shifts. As Preclinical studies have shown that inhibition of the glutamatergic NMDA receptor plays a key role in fast-acting antidepressant effects, nitrous oxide’s pharmacology fits neatly into a growing family of NMDA-targeting treatments.
Teams exploring this pathway describe nitrous oxide as a kind of neural reset button that briefly disrupts entrenched patterns of brain activity and allows healthier circuits to reassert themselves. The Penn group, for example, has framed the gas as a “brain wake-up call,” with The Penn team, working with nitrous oxide, focusing on how short exposures can alter connectivity in mood-related networks. In parallel, Philip J Cowen has emphasized in his analysis that Philip Cowen highlights how NMDA modulation sits alongside changes in GABAergic and other systems, suggesting that nitrous oxide’s antidepressant effects likely arise from a coordinated shift in several neurotransmitter pathways rather than a single receptor flip.
What a nitrous oxide depression session actually looks like
In the clinical trials that have captured so much attention, nitrous oxide is not a casual sniff but a structured medical procedure. Participants typically sit or recline in a monitored setting and breathe a controlled mixture of nitrous oxide and oxygen through a mask for a defined period, often between 20 and 60 minutes, while clinicians track vital signs and mental state. Reports describing these protocols note that Trials indicate nitrous oxide may be delivered via a mask for 20–60 minutes, with doses adjusted to balance antidepressant effects against the risk of nausea, dizziness, or excessive sedation.Outside research settings, some clinics are already adapting similar protocols for patients who have not responded to other treatments, though always within a medical framework rather than a spa-like experience. Practices that offer Nitrous Oxide Inhalation Treatments describe sessions in which patients inhale the gas under supervision, then recover on site until they are fully alert, with some centers emphasizing that people can resume normal activities, including driving, once the acute effects have worn off. That blend of structure and relative convenience is part of what makes nitrous oxide so appealing compared with more logistically demanding interventions like multi-hour ketamine infusions.
How fast the mood lift arrives, and how long it lasts
The central promise of nitrous oxide for depression is speed. Instead of waiting weeks for a pill to build up in the bloodstream, some patients in controlled trials have reported feeling lighter, less hopeless, or more engaged with life within hours of a single session. A major analysis of randomized trials found that The analysis found that a few nitrous oxide breaths could rapidly improve core depression domains such as low mood, anhedonia, and anxiety, with measurable changes appearing on standardized rating scales soon after treatment.
What has surprised many clinicians is not just the quick onset but the durability of some responses. In one closely watched trial, the new study, published in Science Translational Medicine, reported that people with severe depression experienced improvements that persisted for upwards of two weeks after a single nitrous oxide session. Other work summarized in a broad review has concluded that A review by researchers from the University of Birmingham and the University of Oxford supports the idea of immediate relief in controlled settings, while also noting that longer follow-up and repeated dosing studies are needed to understand how long benefits can realistically last in everyday practice.
Single sessions, repeated doses, and who seems to benefit
One of the most practical questions for patients and clinicians is whether nitrous oxide will be a one-off reset or a recurring appointment. Early work suggested that even a single exposure could make a meaningful difference, with Researchers discovered that a single nitrous oxide session improved symptoms in people with hard-to-treat depression, echoing the Science Translational Medicine findings of benefits lasting up to two weeks. Those results have fueled the idea that nitrous oxide could be used as a rapid bridge for people in crisis, buying time while slower-acting therapies take hold.More recent work, however, suggests that repeated dosing may deepen and extend the antidepressant effect. A synthesis of clinical data has concluded that Strong evidence, but limited numbers, indicate that repeated dosing over several weeks leads to more durable improvements in major depressive disorder, especially when patients are followed for extended periods. That pattern mirrors what clinicians have seen with ketamine, where an initial series of treatments is often followed by maintenance sessions, and it raises the possibility that nitrous oxide could be slotted into similar schedules for people with chronic, relapsing illness.
What the big reviews and meta-analyses are actually saying
As individual trials have accumulated, researchers have begun pooling data to see whether the signal holds up across different study designs and patient groups. A large synthesis of controlled trials reported that nitrous oxide is emerging as a surprisingly fast-acting option for people with major or treatment-resistant depression, with consistent reductions in symptom scores compared with placebo or active controls. In that work, Nitrous oxide is emerging as a surprisingly fast-acting option across multiple depression domains, reinforcing the idea that the gas is not just lifting mood in a narrow subset of patients but affecting broader aspects of emotional and cognitive functioning.Another synthesis, focused on the speed and magnitude of response, concluded that Nitrous oxide may offer quick, short-term relief for people with severe or treatment-resistant depression, while emphasizing the need for larger, longer-term studies to clarify safety and durability. That cautious optimism is echoed in the review from the University of Birmingham and the University of Oxford, where A review by researchers from the University of Birmingham and the University of Oxford found that controlled nitrous oxide sessions can offer immediate relief, but also highlighted that many of the existing trials are small, with protocol papers still in progress and limited data on long-term outcomes.
Safety, side effects, and why recreational use is a different story
Any discussion of nitrous oxide for depression has to grapple with safety, especially given the gas’s reputation as a party drug. In medical settings, nitrous oxide is a short-acting inhaled anesthetic that has been used for decades to manage pain and anxiety, with a well-characterized profile of side effects such as nausea, dizziness, and, at higher doses, sedation. Clinical guidance notes that Nitrous oxide (N20) is a type of short-acting anesthetic that is generally safe when administered by trained professionals who can adjust the concentration, ensure adequate oxygen, and monitor for rare complications like changes in blood pressure or breathing.The risks look very different outside that controlled environment. Chronic or heavy recreational use of nitrous oxide can deplete vitamin B12, damage nerves, and in extreme cases cause serious neurological problems, which is one reason researchers are careful to distinguish clinical dosing from balloon or cartridge misuse. Commentators like Philip J Cowen have stressed that Preclinical and clinical work on NMDA-targeting drugs must be paired with rigorous safety monitoring as new treatment modalities are being established. Clinics that already offer nitrous oxide for pain or anxiety, such as those describing Why Choose Nitrous Oxide Treatments, emphasize screening for contraindications, limiting exposure time, and ensuring that patients recover fully before leaving, practices that will be essential if depression protocols move into wider use.
How nitrous oxide compares with ketamine and standard antidepressants
For patients and clinicians, nitrous oxide will inevitably be compared with ketamine, another anesthetic that has moved into the depression space, and with more familiar antidepressant pills. Both nitrous oxide and ketamine act on glutamatergic systems and NMDA receptors, but nitrous oxide’s effects are even shorter in duration, with the gas clearing the body within minutes after inhalation stops. Analyses of mood outcomes suggest that Nitrous oxide (laughing gas) has shown early promise that is comparable in speed to ketamine, though the depth and duration of response may differ, and the optimal dosing schedules for each are still being refined.
Compared with standard antidepressants, nitrous oxide’s main advantage is its rapid onset, which could be life-saving for people in acute crisis or those who have cycled through multiple medications without relief. At the same time, traditional drugs remain the backbone of long-term depression management, in part because they can be taken at home and have decades of safety data. Commentaries like Philip Cowen’s discussion of NMDA-based treatments argue that nitrous oxide and similar agents are likely to complement, rather than replace, existing therapies, perhaps serving as rapid “rescue” options or as catalysts that make patients more receptive to psychotherapy and lifestyle changes.
Where the research goes next, and what patients should watch for
Despite the excitement, nitrous oxide for depression is still in the experimental phase, with key questions unanswered about who benefits most, how often treatments should be repeated, and how to integrate the gas into broader care plans. Ongoing work at Washington University School of Medicine in St. Louis and the University of Chicago is probing different concentrations and session frequencies, building on the finding that Researchers at Washington University School of Medicine in St. Louis and the University of Chicago could relieve symptoms in treatment-resistant patients. At the same time, teams like While its nickname hints at euphoric effects, it acts as a sedative in some contexts are exploring how changes in brain activity during and after nitrous oxide exposure translate into lasting mood shifts.For patients following these developments, the most important thing is to distinguish between rigorously tested medical protocols and informal or recreational use. Reviews that conclude Nitrous oxide may offer quick, short-term relief for people with severe depression also stress that larger, longer-term studies are needed before the gas can be widely recommended. As more protocol papers move from planning to publication, and as clinics refine how they deliver and monitor nitrous oxide sessions, I expect the conversation to shift from “could this work” to “how do we use it responsibly,” with patients, researchers, and regulators all weighing in on where laughing gas fits in the evolving landscape of depression care.
More from MorningOverview